Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 6/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | RXRG | P48443 | 1/20 | 0.40 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.38 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.38 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.38 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.38 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.38 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.34 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.34 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.34 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.34 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.34 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19129490 | 0.84 | IDO1 (0.57) | TACR1IDO1CACNA1FCACNA1DCACNA1S | |
| SCHEMBL20698647 | 0.84 | GLA (0.37) | TACR1MRGPRX4 | |
| SCHEMBL20698868 | 0.83 | IDO1 (0.44) | TACR1MRGPRX4IDO1RXRARXRG | |
| SCHEMBL13018926 | 0.80 | RXRA (0.43) | MRGPRX4IDO1RXRARXRGTAS2R14 | |
| SCHEMBL25869234 | 0.78 | TACR1 (0.34) | TACR1MRGPRX4XDH | |
| SCHEMBL172834 | 0.77 | RXRA (0.46) | TACR1MRGPRX4IDO1RXRARXRG | |
| SCHEMBL20980657 | 0.76 | GRM5 (0.38) | TACR1MRGPRX4IDO1 | |
| SCHEMBL18252840 | 0.76 | RXRA (0.40) | MRGPRX4IDO1RXRARXRGTAS2R14 | |
| SCHEMBL17319636 | 0.75 | RXRA (0.47) | TACR1MRGPRX4IDO1RXRARXRG | |
| SCHEMBL18255653 | 0.74 | LOXL2 (0.47) | TACR1MRGPRX4RXRARXRGTAS2R14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708326-B2 | Immunomodulator compounds | CHEMOCENTRYX, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20210236476-A1 | METHODS OF TREATING CANCER WITH SMALL MOLECULE PD-L1 INHIBITORS | CHEMOCENTRYX, INC. | 2021-08-05 | — | — | US | disclosed |
| US-20210147356-A1 | IMMUNOMODULATOR COMPOUNDS | CHEMOCENTRYX, INC. | 2021-05-20 | — | — | US | disclosed |
| US-20190144389-A1 | DEUTERATED COMPOUNDS AS IMMUNOMODULATORS | CHEMOCENTRYX, INC. | 2019-05-16 | — | — | US | disclosed |
| US-20190135745-A1 | IMMUNOMODULATOR COMPOUNDS | CHEMOCENTRYX, INC. | 2019-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135745-A1 | IMMUNOMODULATOR COMPOUNDS | IL2, FCGRT, IFNG | TACR1 329/4885MRGPRX4 95/4885IDO1 71/4885 |
| US-11708326-B2 | Immunomodulator compounds | IL2, FCGRT, IFNG | TACR1 329/4885MRGPRX4 95/4885IDO1 71/4885 |
| US-20190144389-A1 | DEUTERATED COMPOUNDS AS IMMUNOMODULATORS | C3AR1, C5AR1, C5AR2 | TACR1 147/4885MRGPRX4 48/4885IDO1 127/4885 |
| US-20210147356-A1 | IMMUNOMODULATOR COMPOUNDS | IL2, FCGRT, IFNG | TACR1 329/4885MRGPRX4 95/4885IDO1 71/4885 |
| US-20210236476-A1 | METHODS OF TREATING CANCER WITH SMALL MOLECULE PD-L1 INHIBITORS | CD4, CD274, PDCD1 | TACR1 785/4885MRGPRX4 1078/4885IDO1 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.